We rank companies based on fund manager, research analyst and news sentiment
AYTU stock icon

AYTU BioPharma


About: Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

Employees: 150

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

74% more capital invested

Capital invested by funds: $4.66M [Q3] → $8.11M (+$3.45M) [Q4]

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

5.64% more ownership

Funds ownership: 45.64% [Q3] → 51.28% (+5.64%) [Q4]

0% more funds holding

Funds holding: 22 [Q3] → 22 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Research analyst outlook

We haven’t received any recent analyst ratings for AYTU.

Financial journalist opinion